Advertisement

Drugs and Phytochemicals

  • Madhumita Roy
  • Amitava Datta
Chapter

Abstract

Plant-derived substances, or phytochemicals, have been used for treating many diseases from ancient times. In this chapter we give a broad overview of the phytochemicals that are used as drugs, with a focus on the drugs that are used in chemotherapy. We start with a classification of anticancer drugs and their use in chemotherapy. We then discuss the mechanisms through which these drugs kill cancer cells. We then give an overview of how phytochemicals are used for treating many different diseases. Finally, we discuss the use of phytochemicals that have shown promise as anticancer drugs and agents.

References

  1. 1.
    J. Achan, A.O. Talisuna, A. Erhart, A. Yeka, J.K. Tibenderana, F.N. Baliraine, P.J. Rosenthal, U. D’Alessandro, Quinine, an old anti-malarial drug in a modern world: Role in the treatment of malaria. Malar. J. 10(1), 1–12 (2011)CrossRefGoogle Scholar
  2. 2.
    Y. Alster, D. Varssano, A. Loewenstein, M. Lazar, Delay of corneal wound healing in patients treated with colchicine. Ophthalmology 104(1), 118–119 (1997)PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Z.I. Arshad, A. Amid, F. Yusof, I. Jaswir, K. Ahmad, S.P. Loke, Bromelain: An overview of industrial application and purification strategies. Appl. Microbiol. Biotechnol. 98(17), 7283–7297 (2014)PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    U. Bachrach, Y.C. Wang, Cancer therapy and prevention by green tea: Role of ornithine decarboxylase. Amino Acids 22(1), 1–13 (2002)PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    M.J. Balunas, A.D. Kinghorn, Drug discovery from medicinal plants. Life Sci. 78, 431–441 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    U. Banik, S. Parasuraman, A.K. Adhikary, N.H. Othman, Curcumin: The spicy modulator of breast carcinogenesis. J. Exp. Clin. Cancer Res. 36, 98 (2017)PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    S. Basu, M. Zeng, T. Yin, S. Gao, M. Hu, Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1015–1016, 34–41 (2016)CrossRefGoogle Scholar
  8. 8.
    J. Biswas, M. Roy, A. Mukherjee, Anticancer drug development based on phytochemicals. J. Drug Discov. Deve. Deliv. 2(1), 1012–1017 (2015)Google Scholar
  9. 9.
    W.C. Bowman, S.N. Webb, Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat. J. Pharm. Pharmacol. 24(10), 762–772 (1972)PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Cancer Treatment & Survivorship Facts & Figures 2016-2017. (American Cancer Society, Atlanta, 2016)Google Scholar
  11. 11.
    H. Caraballo, Emergency department management of mosquito-borne illness: Malaria, dengue, and west nile virus. Emerg. Med. Pract. 16(5), 1–23 (2014). Archived from the original on 2016-08-01. “Malaria Fact sheet N°94”. WHO. March 2014. Archived from the original on 3 September 2014. Retrieved 28 August 2014PubMedPubMedCentralGoogle Scholar
  12. 12.
    S. Chakraborty, M. Roy, B. Hazra, R.K. Bhattacharya, Induction of apoptosis in human cancer cell lines by diospyrin, a plant derived bisnaphthoquinonoid and its synthetic derivatives. Cancer Lett. 188, 85–93 (2002)CrossRefGoogle Scholar
  13. 13.
    S. Chakraborty, M. Roy, A.K. Taraphdar, R.K. Bhattacharya, Cytotoxic effect root extract of Tiliacora racemosa and oil of Semecarpus anacardium nut in human tumor cells. Phytother. Res. 18(8), 595–600 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    K. Chanprapaph, V. Vachiramon, P. Rattanakaemakorn, Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management. Dermatol. Res. Pract. 2014, 734249 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    G.M. Cragg, D.J. Newman, A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod. 67(2), 232–244 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    G. Cravotto, L. Boffa, L. Genzini, D. Garella, Phytotherapeutics: An evaluation of the potential of 1000 plants. J. Clin. Pharm. Ther. 35(1), 11–48 (2010)PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    N. Dalbeth, T.J. Lauterio, H.R. Wolfe, Mechanism of action of colchicine in the treatment of gout. Clin. Ther. 36(10), 1465–1479 (2014)PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Y. Damayanthi, J.W. Lown, Podophyllotoxins: Current status and recent developments. Curr. Med. Chem. 5(3), 205–252 (1998)PubMedPubMedCentralGoogle Scholar
  19. 19.
    Y. DENG, E. VERRON, R. ROHANIZADEH, Molecular mechanisms of anti-metastatic activity of curcumin. Anticancer Res. 36(11), 5639–5647 (2016)PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    P.M. Dewick, Medicinal Natural Products: A Biosynthetic Approach, 3rd edn. (Wiley, Chichester, 2012), pp. 230–232Google Scholar
  21. 21.
    Q.P. Dou, Molecular mechanisms of green tea polyphenols. Nutr. Cancer 61(6), 827–835 (2009)PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    H.A. Elbaz, T.A. Stueckle, W. Tse, Y. Rojanasakul, C.Z. Dinu, Digitoxin and its analogs as novel cancer therapeutics. Exp. Hematol. Oncol. 1(1), 4 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    M. Frarag, M. Salih Mohammed, I. Foud, W. Ahmed, M. Malik, The role of natural products in drug discovery and development. World J. Pharm. Res. 4(3) (2015)Google Scholar
  24. 24.
    G.F.S. Fernandes, G.D.B. Silva, A.R. Pavan, D.E. Chiba, C.M. Chin, J.L.D. Santos, Epigenetic regulatory mechanisms induced by resveratrol. Nutrients 9(11), 1201 (2017)PubMedCentralCrossRefGoogle Scholar
  25. 25.
    A.V. Gasper, A. Al-Janobi, J.A. Smith, J.R. Bacon, P. Fortun, C. Atherton, M.A. Taylor, C.J. Hawkey, D.A. Barrett, R.F. Mithen, Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli. Am. J. Clin. Nutr. 82, 1283–1291 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    H. Gersmann, J. Aldred, Medicinal tree used in chemotherapy drug faces extinction. The Guardian. Archived from the original on 16 February 2017 (2011)Google Scholar
  27. 27.
    D.S. Goodsell, The molecular perspective: Methotrexate. Oncologist 4(4), 340–341 (1999)PubMedPubMedCentralGoogle Scholar
  28. 28.
    M. Gordaliza, P.A. García, J.M. del Corral, M.A. Castro, M.A. Gómez-Zurita, Podophyllotoxin: Distribution, sources, applications and new cytotoxic derivatives. Toxicon 44(4), 441–459 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    J.L. Grem, D.F. Hoth, B. Leyland-Jones, S.A. King, R.S. Ungerleider, R.E. Wittes, Teniposide in the treatment of leukemia: A case study of conflicting priorities in the development of drugs for fatal diseases. J. Clin. Oncol. 6(2), 351–379 (1988)PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    S.C. Gupta, J.H. Kim, S. Prasad, B.B. Aggarwal, Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 29(3), 405–434 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    S.S. Hecht, S.G. Carmella, P.M. Kenney, S.H. Low, K. Arakawa, M.C. Yu, Effects of cruciferous vegetable consumption on urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in singapore Chinese. Cancer Epidemiol. Biomark. Prev. 13(6), 997–1004 (2004)Google Scholar
  32. 32.
    T. Heinonen, W. Gaus, Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgos biloba leaf extract. Toxicology 327C(1), 95–115 (2015)CrossRefGoogle Scholar
  33. 33.
    M. Heinrich, H.L. Teoh, Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J. Ethnopharmacol. 92(2–3), 147–162 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    T.M. Henagan, W.T. Cefalu, D.M. Ribnicky, R.C. Noland, K. Dunville, W.W. Campbell, L.K. Stewart, L.A. Forney, T.W. Gettys, J.S. Chang, C.D. Morrison, In vivo effects of dietary quercetin and quercetin-rich red onion extract on skeletal muscle mitochondria, metabolism, and insulin sensitivity. Genes Nutr. 10(1), 2 (2015)Google Scholar
  35. 35.
    S.B. Horwitz, Taxol (paclitaxel): Mechanisms of action. Ann. Oncol. 5(Suppl 6), S3–S6 (1994)PubMedPubMedCentralGoogle Scholar
  36. 36.
    N.E. Hynes, H.A. Lane, ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341–354 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    M. Islam, C.M.D. Rafael, Anticancer prospection of salicin, a historical origin of aspirin. Int. J. Med. 5, 264–265 (2017)CrossRefGoogle Scholar
  38. 38.
    W. Jasek (ed.), Austria-Codex (in German), 62nd edn. (Österreichischer Apothekerverlag, Vienna, 2007), pp. 8855–8856Google Scholar
  39. 39.
    G. Jin, X.R. He, L.P. Chen, The protective effect of ginko bilboa leaves injection on the brain dopamine in the rat model of cerebral ischemia/reperfusion injury. Afr. Health Sci. 14(3), 725–728 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    I. Johnson, Phytochemicals and cancer. Proc. Nutr. Soc. 66, 207–215 (2007)PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    H.Y. Kim, O.H. Kim, M.K. Sung, Effects of phenol-depleted and phenol-rich diets on blood markers of oxidative stress, and urinary excretion of quercetin and kaempferol in healthy volunteers. J. Am. Coll. Nutr. 22(3), 217–223 (2003)PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    B. Kumar, S. Singh, I. Skvortsova, V. Kumar, Promising targets in anti-cancer drug development: Recent updates. Curr. Med. Chem. 24(42), 4729–4752 (2017)PubMedPubMedCentralGoogle Scholar
  43. 43.
    V. Kurowski, H. Iven, H. Djonlagic, Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Intensive Care Med. 18(7), 439–442 (1992)PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    J.M. Langenhan, N.R. Peters, I.A. Guzei, F.M. Hoffmann, J.S. Thorson, Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc. Natl. Acad. Sci. U. S. A. 102(35), 12305–12310 (2005)PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    E. Longstaff, G. von Krogh, Condyloma eradication: self-therapy with 0.15–0.5% podophyllotoxin versus 20–25% podophyllin preparations--an integrated safety assessment. Regul. Toxicol. Pharmacol. 33(2), 117–137 (2001)PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    K.A. Lyseng-Williamson, C. Fenton, Docetaxel: A review of its use in metastatic breast cancer. Drugs 65(17), 2513–2531 (2005)PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    M. Martínez-Castillo, J. Pacheco-Yepez, N. Flores-Huerta, P. Guzmán-Téllez, R.A. Jarillo-Luna, L.M. CárdenaJs-Jaramillo, R. Campos-Rodríguez, M. Shibayama, Flavonoids as a natural Treatment against Entamoeba histolytica. Front. Cell. Infect. Microbiol. 8, Article 209 (2018)PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    J. Mendelsohn, J. Baselga, The EGF receptor family as targets for cancer therapy. Oncogene 19(56), 6550–6565 (2000)PubMedCrossRefGoogle Scholar
  49. 49.
    L. Menger, E. Vacchelli, O. Kepp, A. Eggermont, E. Tartour, L. Zitvogel, G. Kroemer, L. Galluzzi, Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology 2(2), e23082 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    H. Modjtahedi, S. Essapen, Epidermal growth factor receptor inhibitors in cancer treatment: Advances, challenges and opportunities. Anti-Cancer Drugs 20(10), 851–855 (2009)PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    F. Mojab, Antimalarial natural products: a review. Avicenna J. Phytomed. 2(2), 52–62 (2012)PubMedPubMedCentralGoogle Scholar
  52. 52.
    M.A. Morse, S.D. LaGreca, S.G. Amin, F.-L. Chung, Effects of Indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(Methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK) and on the metabolism and disposition of NNK in A/J Mice. Cancer Res. 50, 2613–2617 (1990)PubMedPubMedCentralGoogle Scholar
  53. 53.
    N. Murawski, M. Pfreundschuh, New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 11(11), 1074–1085 (2010)PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    P.B. Murphy, M.J. Barrett, Morphine, [Updated 2019 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 January. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526115/
  55. 55.
    T.M. Nicholson, W.A. Ricke, Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 82(4–5), 184–199 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    N. Normanno, A. de Luca, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, A. Carotenuto, G. De Feo, F. Caponigro, D.S. Salomon, Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1), 2–16 (2006)PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    J. O’Leary, F.M. Muggia, Camptothecins: A review of the development and schedules of administration. Eur. J. Cancer 34(10), 1500–1508 (1998)PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    K.S. Park, A systematic review on anti-inflammatory activity of Harpagoside. J. Biochem. Mol. Biol. Res. 2(3), 166–169 (2016)CrossRefGoogle Scholar
  59. 59.
    H.B. Patisaul, W. Jefferson, The pros and cons of phytoestrogens. Front. Neuroendocrinol. 31(4), 400–419 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    T. Pirttila, G. Wilcock, L. Truyen, C.V. Damaraju, Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: Multicenter trial. Eur. J. Neurol. 11(11), 734–741 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    E. Pisha, H. Chai, I.S. Lee, T.E. Chagwedera, N.R. Farnsworth, G.A. Cordell, C.W. Beecher, H.H. Fong, A.D. Kinghorn, D.M. Brown, M.C. Wani, M.E. Wall, T.J. Hieken, T.K. Das Gupta, J.M. Pezzuto, Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. 1(10), 1046–1051 (1995)PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Y. Pommier, Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer 6(10), 789–802 (2006)PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    X. Qian, T. Melkamu, P. Upadhyaya, F. Kassie, Indole-3-carbinol inhibited tobacco smoke carcinogen-induced lung adenocarcinoma in A/J mice when administered during the post-initiation or progression phase of lung tumorigenesis. Cancer Lett. 311(1), 57–65 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    K. Raedschelders, D.M. Ansley, D.D. Chen, The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol. Ther. 133, 230–255 (2012)PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    A.H. Rahmani, M.A. Al Zohairy, S.M. Aly, M.A. Khan, Curcumin: A potential candidate in prevention of cancer via modulation of molecular pathways. Biomed. Res. Int. 2014, 761608 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    P.T.R. Rajagopalan, Z. Zhang, L. McCourt, M. Dwyer, S.J. Benkovic, G.G. Hammes, Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics. Proc. Natl. Acad. Sci. U. S. A. 99(21), 13481–13486 (2002)PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    J. Ravindran, S. Prasad, B.B. Aggarwal, Curcumin and Cancer cells: How many ways can curry kill tumor cells selectively? AAPS J. 11(3), 495–510 (2009)PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    D.J. Reuland, S. Khademi, C.J. Castle, D.C. Irwin, J.M. McCord, B.F. Miller, K.L. Hamilton, Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress. Free Radic. Biol. Med. 56, 102–111 (2013)PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    I.M.C.M. Rietjens, J. Louisse, K. Beekmann, The potential health effects of dietary phytoestrogens. Br. J. Pharmacol. 174(11), 1263–1280 (2017)PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    A. Rocha, L. Wang, M. Penichet, M. Martins-Green, Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res. Treat. 136(3), 647–658 (2012)PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    G. Sa, T. Das, Anti cancer effects of curcumin: Cycle of life and death. Cell Div 3, 14 (2008)PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    R. Sandhir, Mehrotra, Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: Implications in Huntington’s disease, Biochimica et Biophysica Acta (BBA) - Mol. Basis Dis. 1832(3), 421–430 (2013)Google Scholar
  73. 73.
    R. Saller, R. Brignoli, J. Melzer, R. Meier, An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch. Komplementmed. 15(1), 9–20 (2008)PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    F.P. Santos, H. Kantarjian, A. Quintás-Cardama, J. Cortes, Evolution of therapies for chronic myelogenous leukemia. Cancer J. 17(6), 465–476 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    R.-N. Seth, Cancer mechanisms, why cancer and inflammation? YALE J. Biol. Med. 79, 123–130 (2006)Google Scholar
  76. 76.
    P. Sharma, S.F. McClees, F. Afaq, Pomegranate for prevention and treatment of cancer: An update. Molecules 22(1), 177 (2017)PubMedCentralCrossRefGoogle Scholar
  77. 77.
    P.G. Shekelle, S.J. Newberry, J.D. FitzGerald, A. Motala, C.E. O’Hanlon, A. Tariq, A. Okunogbe, R. Shanman, Management of Gout: A systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 166(1), 37–51 (2017)PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    M. Shelley, C. Harrison, B. Coles, J. Staffurth, T.J. Wilt, M.D. Mason, Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst. Rev. 4, CD005247 (2006)Google Scholar
  79. 79.
    S. Howard, Illustrated pharmacology memory cards: Pharmnemonics. Minireview, p. 13. ISBN 1-59541-101-1. (2008)Google Scholar
  80. 80.
    X.O. Shu, Y. Zheng, H. Cai, K. Gu, Z. Chen, W. Zheng, W. Lu, Soy food intake and breast Cancer survival. JAMA 302(22), 2437–2443 (2009)PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    B.N. Singh, S. Shankar, R.K. Srivastava, Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 82(12), 1807–1821 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    S. Singh, B. Sharma, S.S. Kanwar, A. Kumar, Lead phytochemicals for anticancer drug development. Front. Plant Sci. 7, 1667 (2016)PubMedPubMedCentralGoogle Scholar
  83. 83.
    W.J. Slichenmyer, E.K. Rowinsky, R.C. Donehower, S.H. Kaufmann, The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85(4), 271–291 (1993)PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    J.S. Smith, 2007. and The Food Safety Consortium. Brush on the marinade, hold off the cancerous compounds. Science Daily 2007; June 28Google Scholar
  85. 85.
    K. Stromgaard, K. Nakanishi, Chemistry and biology of terpene Trilactones from Ginkgo Biloba. Angew. Chem. Int. Ed. 43(13), 1640–1658 (2004)CrossRefGoogle Scholar
  86. 86.
    S.-Y. Sun, N. Hail, R. Lotan, Apoptosis as a novel target for Cancer chemoprevention. J. Natl. Cancer Inst. 96(9), 662–672 (2004)PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    D.N. Syed, J.C. Chamcheu, V.M. Adhami, H. Mukhtar, Pomegranate extracts and Cancer prevention: Molecular and cellular activities. Anti Cancer Agents Med. Chem. 13(8), 1149–1161 (2013)CrossRefGoogle Scholar
  88. 88.
    C.H. Takimoto, E. Calvo, Principles of Oncologic Pharmacotherapy, in Cancer Management: A Multidisciplinary Approach, ed. by R. Pazdur, L. D. Wagman, K. A. Camphausen, W. J. Hoskins, Cmp United Business Media, USA (2009)Google Scholar
  89. 89.
    W.F. Taylor, E. Jabbarzadeh, The use of natural products to target cancer stem cells. Am. J. Cancer Res. 7(7), 1588–1605 (2017)PubMedPubMedCentralGoogle Scholar
  90. 90.
    R. Thirumaran, G.C. Prendergast, P. Gilman, Chapter 7: Cytotoxic chemotherapy in clinical treatment of cancer, in Cancer Immunotherapy: Immune Suppression and Tumor Growth, ed. by G. C. Prendergast, E. M. Jaffee, Academic Press, USA (Academic/Elsevier, Amsterdam/Boston, 2007), pp. 101–116CrossRefGoogle Scholar
  91. 91.
    R. Thomas, E. Butler, F. Macchi, M. Williams, Phytochemicals in cancer prevention and management? British J. Med Pract. 8(2), a815 (2015)Google Scholar
  92. 92.
    J. Tian, X. Ye, Y. Shang, Y. Deng, K. He, X. Li, Preparative isolation and purification of harpagoside and angroside C from the root of Scrophularia ningpoensis Hemsley by high-speed counter-current chromatography. J. Sep. Sci. 35, 2659–2664 (2012)PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    C. Tsioufis, C. Thomopoulos, Combination drug treatment in hypertension. Pharmacol. Res. 125(Pt B), 266–271 (2017)PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    S. Upadhyay, M. Dixit, Role of polyphenols and other phytochemicals on molecular signaling. Oxidative Med. Cell. Longev. 2015, 504253 (2015)CrossRefGoogle Scholar
  95. 95.
    S. Usai, L. Grazzi, G. Bussone, Gingkolide B as migraine preventive treatment in young age: Results at 1-year follow-up. Neurol. Sci. 32(Suppl 1), I97–I99 (2011)Google Scholar
  96. 96.
    M.E. Van Meter, E.S. Kim, Bevacizumab: Current updates in treatment. Curr. Opin. Oncol. 22, 586–591 (2010)PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    W. Voigt, S. Matsui, M.B. Yin, W.C. Burhans, H. Minderman, Y.M. Rustum, Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res. 18(5A), 3499–3505 (1998)PubMedPubMedCentralGoogle Scholar
  98. 98.
    W.P. Wang, N. Liu, Q. Kang, Simultaneous determination by UPLC-MS/MS of seven bioactive compounds in rat plasma after oral administration of Ginkgos biloba tablets: Application to a pharmacokinetic study. J. Zhejiang Univ. Sci. B. 15(11), 929–939 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    T. Weber, Rauwolfia: Gandhi’s Favourite Tranquiliser? South Asia J. South Asian Stud. 41(3), 567–578 (2018)CrossRefGoogle Scholar
  100. 100.
    R. Wilken, M.S. Veena, M.B. Wang, E.S. Srivatsan, Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 10, 12 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    I.U. Willcockson, A. Hong, R.P. Whisenant, J.B. Edwards, H. Wang, H.K. Sarkar, S.E. Pedersen, Orientation of d-tubocurarine in the muscle nicotinic acetylcholine receptor-binding site. J. Biol. Chem. 277(44), 42249–42258 (2002)PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    C.D. Willey, J.A. Bonner, Interaction of chemotherapy and radiation, in Clinical Radiation Oncology, 3rd edn., Elsevier, Philadelphia (2012)Google Scholar
  103. 103.
    H. Xu, M. Lv, X. Tian, A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr. Med. Chem. 16(3), 327–349 (2009)PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    C.S. Yang, H. Wang, J.X. Chen, J. Zhang, Effects of tea Catechins on Cancer signaling pathways. Enzyme 36, 195–221 (2014)CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Madhumita Roy
    • 1
  • Amitava Datta
    • 2
  1. 1.Environmental Carcinogenesis and ToxicologyChittaranjan National Cancer InstituteKolkataIndia
  2. 2.Department of Computer Science and Software EngineeringThe University of Western AustraliaPerthAustralia

Personalised recommendations